India's CRDMO sector growth potential at $22 - $25 bn by 2035: BCG-IPSO Report

Report states that India's CRDMO sector is poised for rapid growth with strong fundamentals and global realignments, focusing on leading-edge science and technology, Excerpts from the report

- 

The Indian Contract Research, Development, and Manufacturing Organization (CRDMO) sector is at an inflection point, with the potential to grow to $22 - $25 billion by 2035, as revealed in a new report, Unleashing the Tiger: Indian CRDMO Sector 2025, published by Boston Consulting Group (BCG) and Innovative Pharmaceutical Services Organisation (IPSO). The report highlights India's strong foundation in small molecule capabilities, sustainable cost advantages and emerging biologics expertise, positioning the country as a global leader in pharmaceutical innovation.

Key findings from the report

India’s CRDMO market is growing at a 15 per cent CAGR, outpacing global industry growth, fueled by its cost advantage over the West and 90 per cent faster project startup times.

Global supply chain realignments are unlocking a $10 billion opportunity for Indian CRDMOs, with Western pharma companies looking for alternative hubs.

New modalities such as Antibody Drug Conjugates (ADCs), DNA and RNA therapeutics are witnessing a 25-35 per cent annual growth, providing India with an opportunity to leapfrog in innovation.

Indian biotech and pharma innovation is accelerating, backed by over Rs 25,000 crore in government funding to foster a self-sufficient, local innovation-driven ecosystem.